Compare RVTY & XP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVTY | XP |
|---|---|---|
| Founded | 1937 | 2001 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Investment Bankers/Brokers/Service |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 10.1B |
| IPO Year | 1994 | 2019 |
| Metric | RVTY | XP |
|---|---|---|
| Price | $92.36 | $19.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $113.00 | $22.67 |
| AVG Volume (30 Days) | 1.2M | ★ 6.5M |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | 0.31% | ★ 0.97% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $3,311,822,000.00 | N/A |
| Revenue This Year | $6.34 | $19.15 |
| Revenue Next Year | $5.10 | $13.67 |
| P/E Ratio | $44.32 | ★ $11.42 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $81.36 | $12.20 |
| 52 Week High | $119.02 | $23.13 |
| Indicator | RVTY | XP |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 45.71 |
| Support Level | $88.42 | $18.05 |
| Resistance Level | $95.99 | $20.37 |
| Average True Range (ATR) | 3.31 | 1.08 |
| MACD | -0.36 | -0.37 |
| Stochastic Oscillator | 27.11 | 22.91 |
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.